RxDoctor Payments Data

Ofsman Quintana, MD

Cardiovascular Disease · McAllen, TXNPI 1689679920

Payments from drug & device makers

$105,122in general payments, 2019–2025

Across 883 payments — averaging $119.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$19K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$13K
  • E.r. Squibb & Sons, L.L.C.$12K
  • AstraZeneca$11K
  • Abbott$7K
  • Pfizer$6K
  • plus $37K from 47 others

What the payments were for

  • Consulting fees$8001%
  • Speaking & faculty fees$16,59929%
  • Travel & lodging$11,34320%
  • Food & beverage$29,02450%
  • Education$520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$105,122 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$113,207
Medicare patients
203
Services billed
869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban193$258,615
EliquisApixaban145$179,842
EntrestoSacubitril/Valsartan59$94,496
BrilintaTicagrelor26$19,271
Ranolazine ErRanolazine63$8,762
Cilostazol181$4,775
ClopidogrelClopidogrel Bisulfate336$4,287
Metoprolol Succinate215$3,352
Labetalol Hcl106$2,865
Atorvastatin Calcium190$2,479
Losartan Potassium144$1,861
Isosorbide Mononitrate ErIsosorbide Mononitrate138$1,656
Nifedipine ErNifedipine27$1,115
Amlodipine Besylate146$1,108
Lisinopril89$1,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$695$258,615193 claims
PfizerEliquis$6,131$179,842145 claims
NovartisEntresto$1,287$94,49659 claims
AstraZenecaBrilinta$10,605$19,27126 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →